| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9668981 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic based polymers |
Oct, 2025
(2 years from now) | |
| US8632802 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(2 years from now) | |
| US9034370 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(2 years from now) | |
Daytrana is owned by Noven Pharms Inc.
Daytrana contains Methylphenidate.
Daytrana has a total of 3 drug patents out of which 0 drug patents have expired.
Daytrana was authorised for market use on 06 April, 2006.
Daytrana is available in film, extended release;transdermal dosage forms.
Daytrana can be used as method for transdermally delivering a drug to a user in need thereof.
The generics of Daytrana are possible to be released after 07 October, 2025.
Drugs and Companies using METHYLPHENIDATE ingredient
Market Authorisation Date: 06 April, 2006
Treatment: Method for transdermally delivering a drug to a user in need thereof
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
DAYTRANA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic